CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)
0.8400
+0.0100 (1.20%)
At close: Feb 13, 2026
HKG:0775 Revenue
CK Life Sciences Int'l., (Holdings) had revenue of 2.61B HKD in the half year ending June 30, 2025, with 1.03% growth. This brings the company's revenue in the last twelve months to 5.49B, up 2.10% year-over-year. In the year 2024, CK Life Sciences Int'l., (Holdings) had annual revenue of 5.52B with 3.76% growth.
Revenue (ttm)
5.49B
Revenue Growth
+2.10%
P/S Ratio
1.45
Revenue / Employee
2.84M
Employees
1,935
Market Cap
7.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.52B | 199.94M | 3.76% |
| Dec 31, 2023 | 5.32B | 47.14M | 0.89% |
| Dec 31, 2022 | 5.28B | -126.72M | -2.35% |
| Dec 31, 2021 | 5.40B | 459.77M | 9.30% |
| Dec 31, 2020 | 4.94B | -24.48M | -0.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.74B |
| HBM Holdings | 908.35M |
| Alphamab Oncology | 861.24M |
| Lepu Biopharma | 767.54M |
| Abbisko Cayman | 678.11M |
| Ocumension Therapeutics | 595.79M |
| CStone Pharmaceuticals | 221.89M |
| Mirxes Holding Company | 166.32M |
CK Life Sciences Int'l., (Holdings) News
- 4 months ago - CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs - South China Morning Post
- 4 months ago - TransCode Acquires Polynoma From CK Life Sciences - Nasdaq
- 1 year ago - CK Life’s new CEO counts on Big Pharma experience to boost new drug success, earnings - South China Morning Post